Walter Public Investments Inc. Takes $6.74 Million Position in IDEXX Laboratories, Inc. $IDXX

Walter Public Investments Inc. purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, Holdings Channel.com reports. The firm purchased 9,963 shares of the company’s stock, valued at approximately $6,740,000.

A number of other hedge funds have also recently made changes to their positions in IDXX. Elyxium Wealth LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $3,666,459,000. Northwestern Mutual Wealth Management Co. grew its position in shares of IDEXX Laboratories by 63,503.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after purchasing an additional 1,442,174 shares in the last quarter. Norges Bank purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $332,265,000. JPMorgan Chase & Co. grew its position in shares of IDEXX Laboratories by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after purchasing an additional 326,348 shares in the last quarter. Finally, Zurich Insurance Group Ltd FI purchased a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $143,730,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.8%

Shares of NASDAQ:IDXX opened at $563.53 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98. The firm has a fifty day moving average of $564.58 and a 200 day moving average of $637.19. The firm has a market capitalization of $44.45 billion, a PE ratio of 41.50, a price-to-earnings-growth ratio of 3.27 and a beta of 1.58. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned $2.91 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on IDXX shares. Piper Sandler reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. BTIG Research reduced their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.